New cocktail of three drugs shows promise for Tough-to-Treat uterine cancer
NCT ID NCT02755844
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of three drugs—olaparib, metformin, and cyclophosphamide—in 35 women with recurrent advanced endometrial cancer that had already been treated with chemotherapy. The goal was to find a safe dose and see if the combination could stop the cancer from growing. If successful, this could provide a new treatment option for patients with few alternatives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olaparib, metformin, and cyclophosphamide
What this could lead to
If this combination works, it could offer a new treatment option for women with recurrent endometrial cancer who have run out of effective therapies.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply to all patients. The drug combination may cause side effects or fail to control the cancer long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Comité Gynécologique, Institut Gustave Roussy
Villejuif, 94800, France
-
Département d'Oncologie Médicale, Centre Antoine Lacassagne
Nice, 06189, France
-
Département de Cancérologie Cervico-Faciale et Thoracique, Centre Oscar Lambret
Lille, 59000, France
-
Service d'Oncologie Médicale, Centre François Baclesse
Caen, 14076, France
-
Service d'Oncologie Médicale, Institut Curie
Paris, 75248, France